RADIANCE-HTN SOLO: Control Durability of BP

In patients with hard-to-control high blood pressure (HBP), both non-pharmacological treatment and lifestyle changes have been useful to improve its control. Renal denevartion (RDN) was assessed as part of this complementary treatment, since some research has shown that this alternative decreases blood pressure (BP) values in different groups treated with either radiofrequency or ultrasound (uRDN).

RADIANCE-HTN SOLO: Durabilidad del control de la TA

RDN durability at 36 months has been reported in the follow-up of the Global SYMPLICITY registries and in the SPYRAL HTN-ON MED trial.

In order to report on office BP (OBP) response and safety in patients treated with uDNR, the 36-month follow-up results of the RADIANCE-HTN SOLO study (changes in OBP with uDNR using the Paradise system) were published.

Inclusion criteria were uncontrolled BP with OBP ≥140/90 mmHg and <180/110 when treated with 0-2 antihypertensive medications (AHM) or controlled BP with OBP <140/90 using 1 or 2 AHMs. Patients included went through a washout period before randomization (uRDN vs. sham procedure). In the 2-to-6-months follow-up, AHM was reintroduced in a standardized fashion.

The efficacy primary endpoint (PEP) was OBP change at 36 months. Baseline medication change was also evaluated at 36 months.

Read also: Adherence to P2Y12 Inhibitors in Acute Coronary Syndrome: Prognosis.

Of 74 patients initially randomized, follow-up data was obtained from 51. Their mean age was 53.9 years old, 66.7% of them were male, 82% were Caucasian, 52.9% were obese, and 7.8% had obstructive sleep apnea. The mean antihypertensive medication was 1.2±0.7 (51% one medication, and 33% two medications).

After the washout required by the study, there was an increase in BP of 9.3±12 mmHg. After to randomization to uRDN, blood pressure decreased to 10.0±14.7 mmHg at 2 months and, upon restarting the usual medication, the antihypertensive effect improved, with a decrease of 17.7±15 mmHg at 6 months. The mean decrease in systolic/diastolic OBP was 18/11 ± 15/9 mmHg, respectively (p < 0.001). Pressure control improved from 29.4% at baseline to 45.1% at 36 months.

There were no significant safety events at follow-up (only one event of renal angioplasty with stenting at 6 months after the procedure).

Conclusions

In this study, there was a decrease in time of -17.7 mmHg from baseline at the 36-month follow-up (with the addition of AHM). This may help to decrease the burden of cardiovascular risk, since, as previously seen, a 5-mmHg reduction in OBP could decrease the risk of major adverse cardiac events by 10%. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial.

Font: Rader, Florian et al. “Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial.” EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, EIJ-D-22-00305. 1 Aug. 2022, doi:10.4244/EIJ-D-22-00305.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

New Carotid PCI All-in-One System

Carotid stenting is equivalent to carotid endarterectomy in terms of major adverse events (death, AMI, and stroke). However, it entails higher risk of minor...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...